Protara Therapeutics, Inc.
TARA · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.10 | 0.09 | 0.68 | -0.08 |
| FCF Yield | -9.58% | -8.51% | -6.67% | -20.66% |
| EV / EBITDA | -6.06 | -6.10 | 1.32 | 0.50 |
| Quality | ||||
| ROIC | -11.18% | -8.68% | -8.34% | -14.25% |
| Gross Margin | 0.00% | 0.00% | 50.00% | 0.00% |
| Cash Conversion Ratio | 0.94 | 0.82 | 1.23 | 0.73 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 16.84% | -58.54% | -10.26% | -9.04% |
| Safety | ||||
| Net Debt / EBITDA | 1.66 | 6.18 | 11.13 | 3.84 |
| Interest Coverage | -10.20 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -4,866.43 | -2,504.82 | 0.00 | -2,458.93 |